Michael King

Michael King is an accomplished pharmaceutical and biotechnology executive with over 30 years of experience in various leadership roles.1 He is currently a Partner at Hibiscus Bioventures, LLC.3 King has held several key positions throughout his career, including:

1. CFO of Primera Therapeutics, a company developing gene editing therapies for mitochondrial diseases.15
2. CFO of Hibiscus Biotechnology.1
3. CBO of Adaptive Phage Therapeutics during its $61 million Series A funding.14
4. CFO and CBO of PDS Biotechnology (PDSB) from 2014 to 2019.1
5. Senior advisor at Akari Therapeutics (AKTX) from 2015 to 2022.1
6. CFO and CBO of Aprecia Pharmaceuticals, where he raised over $70 million in private financing.1
7. CBO of Atrin Pharmaceuticals (now Aprea Therapeutics, APRE).1
8. Member of the U.S. Executive Committee for Sandoz GmbH, a $10 billion subsidiary of Novartis AG.1

King's expertise spans corporate finance, business development, and management consulting. He was formerly a management consultant with McKinsey & Company in its Pharmaceutical and Medical Products practice, based in New York.1 Currently, he also serves as a consultant at BR BioAdvisory Services, providing valuable insights to clients in the life sciences industry.12